bluebird bio, Inc.·4

Apr 12, 4:17 PM ET

Walsh Jeffrey T. 4

4 · bluebird bio, Inc. · Filed Apr 12, 2019

Insider Transaction Report

Form 4
Period: 2019-04-10
Walsh Jeffrey T.
Chief Operating Officer
Transactions
  • Exercise/Conversion

    Stock Option (right to buy)

    2019-04-101,50013,021 total
    Exercise: $24.47Exp: 2024-03-03Common Stock (1,500 underlying)
  • Sale

    Common Stock

    2019-04-10$156.44/sh1,100$172,08541,321 total
  • Exercise/Conversion

    Common Stock

    2019-04-10$24.47/sh+1,500$36,70542,421 total
  • Sale

    Common Stock

    2019-04-10$157.23/sh400$62,89140,921 total
Footnotes (4)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 2, 2018.
  • [F2]The range of prices for the transaction reported on this line was $156.09 to $156.62. The average weighted price was $156.4409. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F3]The range of prices for the transaction reported on this line was $157.09 to $157.38. The average weighted price was $157.2275. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F4]This option vested over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION